NCT05585281 is a Phase 2 clinical trial of Fluzoparib in Ovarian Cancer, sponsored by Yongpeng Wang.

Who is sponsoring NCT05585281?

NCT05585281 is sponsored by Yongpeng Wang.

What drugs are being tested in NCT05585281?

Interventions in NCT05585281: Fluzoparib, QL1101.

What condition does NCT05585281 study?

NCT05585281 studies Ovarian Cancer.

Is NCT05585281 still recruiting?

NCT05585281 is currently status unknown. Last updated 28 July 2023.

Last reviewed 2023-07-28 · How we verify

NCT05585281

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Status unknown Phase 2 Last updated 28 July 2023

What this trial tests

Phase 2 trial testing Fluzoparib in Ovarian Cancer in 25 participants. Status unknown.

Timeline

27 July 2023

Primary endpoint
7 November 2025

22 December 2025

Quick facts

Lead sponsor	Yongpeng Wang
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	27 July 2023
Primary completion	7 November 2025
Estimated completion	22 December 2025
Sites	1 location across China

Drugs / interventions tested

Fluzoparib — full drug profile →
QL1101 — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Yongpeng Wang

Who can join

Adults 18 to 70, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Prospective,Single-Center, Single-Arm, Phase 2 study to evaluate the efficacy and safety of Fluzoparib Combined With QL1101, as maintenance treatment, in patients with Advanced FIGO Stage III or IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or primary peritoneal cancer following front-line platinum-based chemotherapy with QL1101. Eligible participants who achieve complete response (CR) or partial response (PR) following treatment with platinum-based chemotherapy in addition to QL1101 will be enrolled in the study and will receive maintenance treatment with fluzoparib (for up to 2 years) combined with QL1101 (for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of the approximately 5 months of bevacizumab received with chemotherapy) or until disease progression, unacceptable toxicity, participant withdrawal, Investigator's decision, or death, whichever comes first.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fluzoparib

Trials testing the same drug.

NCT07353437 — Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast · Phase 2 · not yet recruiting
NCT07382713 — Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer · Phase 2 · not yet recruiting
NCT07141771 — An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing · Phase 1, PHASE2 · not yet recruiting
NCT06735326 — Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer · Phase 2 · recruiting
NCT06539091 — Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05585281 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yongpeng Wang
Last refreshed: 28 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing